Science

Research and Development

At Jazz, what we’re doing today is transforming the future—of our patients’ lives, of our key therapeutic areas and of the impact we have on the world. We seek scientific breakthroughs in neuroscience and oncology that will result in life-changing medicines and redefine possibilities for patients and their families.

Our R&D approach is patient-centric and proven—we find or create the science that patients need. Jazz begins with a complex, unmet patient need—people who are waiting on the first or a better therapeutic option for their condition—and then we find or create the science that delivers it. We harness the collective talents and expertise of our researchers, scientists, chemists, developers and more to advance our fields of study through our own proprietary programs and assets, and through strategic collaborations with leading innovators, researchers and academia.

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
CombiPlex
Exploratory activities
JZP341
(Long-acting Erwinia asparaginase)
ALL/LBL
Pan-RAF Inhibitor program
Raf & Ras mutant tumors
Undisclosed targets
Ras/Raf/MAP kinase pathway1
Exosome targets
NRAS and up to 4 others)1
Hematological malignancies/solid tumors
Undisclosed targets
Oncology
Undisclosed targets
Cannabinoids
PHASE 1
JZP3243
Oxybate extended-release formulation
JZP351
Low Intensity Dosing for higher risk MDS2
JZP351 + other approved therapies
  • R/R AML or HMA Failure MDS2
  • First-line, fit AML (Phase 1b)
  • Low Intensity Therapy for first-line, unfit AML (Phase 1b)
Additional Cannabinoids
Neonatal hypoxic-ischemic encephalopathy
Additional Cannabinoids
Neuropsychiatry targets

PHASE 2
Suvecaltamide (JZP385)
Essential tremor
Lurbinectedin3
Basket trial: advanced urothelial cancer, large cell neuroendocrine tumor of the lung, HRD+ cancers
JZP351
  • HR-MDS (EMSCO)4
  • Newly diagnosed older adults with HR-AML4
JZP351 + venetoclax
de novo or R/R AML2
JZP1505
PTSD
Additional Cannabinoids

Schizophrenia
Additional Cannabinoids
Autism spectrum disorders

PHASE 3
Lurbinectedin1
1L treatment SCLC in combination with Tecentriq® (atezolizumab)
JZP351
  • AML or HR-MDS >60 yrs (AML18)4
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)4
  • Newly diagnosed <22 yrs with AML (COG)4
Cannabidiol (Epidiolex)3
EMAS

Nabiximols
MS spasticity

Nabiximols3
Spinal cord injury spasticity

REGULATORY
JZP458 (Rylaze)6
(recombinant Erwinia asparaginase)
ALL/LBL
Neuroscience
Oncology
Cannabinoids
1Partnered collaboration.
2Jazz & MD Anderson Cancer Center collaboration study.
3Planned.
4Cooperative group study.
5JZP150 is a fatty acid amide hydrolase inhibitor which modulates the endocannabinoid anandamide.
6FDA approval on June 30, 2021; plan to submit additional data to support U.S. label update

Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.